A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

NCT05933187 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

DRUG: Treatment A: Emraclidine 30mg IR tablets (reference)
DRUG: Treatment B: Emraclidine 30mg IR test tablets 1
DRUG: Treatment C: Emraclidine 30mg IR test tablets 2
DRUG: Treatment D: Emraclidine 30mg IR test tablets 3

Sponsor

Cerevel Therapeutics, LLC